8.7 C
London
Friday, March 29, 2024
HomeFinTechPharmAust: Successfully progresses canine trials and other operations

PharmAust: Successfully progresses canine trials and other operations

Date:

PharmAust: Successfully progresses canine trials and other operations

  • PharmAust (PAA) claims its business progressed “very successfully” in the 2019 December quarter
  • Its phase 2 trials also using monepantel to treat dogs with cancer saw positive progress
  • Then the company is extending the study with a new dosage and hopes to uncover a successful drug for canine treatment
  • The company has submitted and MPL human trial paper for publication in a peer review journal
  • In addition, its wholly-owned subsidiary, Epichem, had a positive quarter and achieved revenue of almost $970,000
  • Shares in PharmAust remain flat and are trading for 9.6 cents each

Related stories

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img